ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Intellectual Property

U.S. noncourt patent challenge system benefits generic drug makers, study says

by Glenn Hess, special to C&EN
September 15, 2018 | APPEARED IN VOLUME 96, ISSUE 37

 

09637-polcon4-court.jpg
Credit: Arthur Lien
Representing Oil States Energy Services before the Supreme Court on Nov. 27, 2017, Allyson N. Ho argued that an administrative process to challenge patents is unconstitutional. The court ruled in favor of the process on April 24.

Generic drug companies that use a low-cost alternative to court litigation to challenge brand-name drug patents are successful nearly half the time, according to a study published in Applied Health Economics & Health Policy (2018, DOI: 10.1007/s40258-018-0420-8). The U.S. Patent & Trademark Office’s inter partes review (IPR) process is quicker and less expensive than court challenges and “can help clear weak patent claims, especially those directed to formulations and methods of use,” say researchers from Harvard Medical School and Brigham & Women’s Hospital. IPR was established in 2012 as a procedure for challenging the validity of a patent before the patent office’s appeals board. The analysis of those challenges shows that generic drug manufacturers used the IPR process to challenge 198 patents covering 134 different drugs between September 2012 and April 2017. In 43% of the cases, generic drug makers succeeded in overturning all patent claims that they challenged. In addition, the proceeding has consistently been completed within 12 months. “In the pharmaceutical market, the inter partes review process can meaningfully contribute to ensuring that invalid patents do not block timely availability of generic drugs,” the researchers conclude.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment